IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 311 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.49 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $20,871,905 | +10.7% | 460,139 | +0.1% | 0.00% | +33.3% |
Q2 2023 | $18,858,044 | +114.7% | 459,616 | +87.0% | 0.00% | +200.0% |
Q1 2023 | $8,782,033 | +5.2% | 245,720 | +11.1% | 0.00% | -66.7% |
Q4 2022 | $8,349,889 | -25.6% | 221,072 | -12.9% | 0.00% | +50.0% |
Q3 2022 | $11,225,000 | +2.5% | 253,770 | -14.2% | 0.00% | -33.3% |
Q2 2022 | $10,952,000 | -5.3% | 295,853 | -5.2% | 0.00% | +50.0% |
Q1 2022 | $11,565,000 | -64.6% | 312,226 | -70.9% | 0.00% | – |
Q4 2021 | $32,702,000 | +98.3% | 1,074,710 | +118.6% | 0.00% | -100.0% |
Q3 2021 | $16,488,000 | -50.9% | 491,566 | -41.6% | 0.00% | -25.0% |
Q2 2021 | $33,586,000 | +17.0% | 841,966 | +31.9% | 0.00% | -20.0% |
Q1 2021 | $28,702,000 | -51.5% | 638,371 | -39.0% | 0.01% | +25.0% |
Q4 2020 | $59,186,000 | +72.7% | 1,046,786 | +44.9% | 0.00% | -42.9% |
Q3 2020 | $34,272,000 | -33.5% | 722,286 | -17.4% | 0.01% | -46.2% |
Q2 2020 | $51,573,000 | +17.5% | 874,706 | -5.8% | 0.01% | -7.1% |
Q1 2020 | $43,908,000 | -47.0% | 928,693 | -32.3% | 0.01% | -41.7% |
Q4 2019 | $82,848,000 | -2.4% | 1,371,422 | -3.2% | 0.02% | -17.2% |
Q3 2019 | $84,857,000 | -55.7% | 1,416,395 | -52.5% | 0.03% | +26.1% |
Q2 2019 | $191,760,000 | +53.5% | 2,983,662 | +93.8% | 0.02% | -54.9% |
Q1 2019 | $124,962,000 | +101.0% | 1,539,506 | +33.9% | 0.05% | +104.0% |
Q4 2018 | $62,162,000 | -12.7% | 1,149,883 | -16.7% | 0.02% | +4.2% |
Q3 2018 | $71,244,000 | +41.7% | 1,381,220 | +14.5% | 0.02% | +41.2% |
Q2 2018 | $50,264,000 | +31.2% | 1,206,223 | +38.8% | 0.02% | +30.8% |
Q1 2018 | $38,318,000 | -5.8% | 869,276 | +7.5% | 0.01% | -7.1% |
Q4 2017 | $40,677,000 | -29.0% | 808,681 | -28.4% | 0.01% | -36.4% |
Q3 2017 | $57,260,000 | +20.1% | 1,129,410 | +20.5% | 0.02% | +10.0% |
Q2 2017 | $47,681,000 | +16.0% | 937,315 | -8.3% | 0.02% | -4.8% |
Q1 2017 | $41,104,000 | -22.9% | 1,022,500 | -8.3% | 0.02% | -22.2% |
Q4 2016 | $53,312,000 | -1.8% | 1,114,600 | -24.8% | 0.03% | +8.0% |
Q3 2016 | $54,282,000 | +38.2% | 1,481,514 | -12.2% | 0.02% | +19.0% |
Q2 2016 | $39,290,000 | -21.3% | 1,686,986 | +36.9% | 0.02% | -19.2% |
Q1 2016 | $49,911,000 | -47.3% | 1,232,358 | -19.5% | 0.03% | -40.9% |
Q4 2015 | $94,789,000 | – | 1,530,589 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tweedy, Browne Co LLC | 3,541,136 | $133,749 | 7.12% |
Bellevue Group AG | 9,743,900 | $368,027,103 | 4.88% |
M28 Capital Management LP | 126,300 | $4,770,351 | 4.55% |
Sicart Associates LLC | 246,258 | $9,301,165 | 3.28% |
Camber Capital Management LP | 1,925,000 | $72,707 | 2.49% |
Privium Fund Management B.V. | 148,807 | $5,557,941 | 2.11% |
Deep Track Capital, LP | 1,205,773 | $45,542,046 | 1.91% |
BVF INC/IL | 1,121,809 | $42,370,726 | 1.79% |
Orbimed Advisors | 1,993,600 | $75,298,272 | 1.44% |
Parkman Healthcare Partners LLC | 141,115 | $5,329,914 | 1.42% |